Solid Biosciences Announces Inducement Grants per Nasdaq Rule 5635(c)(4)

Solid Biosciences Inc. (Nasdaq: SLDB), a company dedicated to creating precision genetic medicines for neuromuscular and cardiac conditions, has awarded 30,949 restricted stock units (RSUs) to four newly hired employees. These RSUs will vest in four equal parts on each one-year anniversary of the employee's start date, stretching over four years. The vesting is contingent on each employee's continuous service with the company through each vesting date.

These stock grants were made under the Company's 2024 Inducement Stock Incentive Plan, aimed to encourage new employees to join the company. The grants are consistent with Nasdaq Listing Rule 5635(c)(4), which governs such inducements.

Solid Biosciences focuses on advancing gene therapy candidates for a variety of severe conditions. Among their projects are SGT-003, which targets Duchenne muscular dystrophy (Duchenne); SGT-501, for treating catecholaminergic polymorphic ventricular tachycardia (CPVT); and AVB-401, aimed at BAG3-mediated dilated cardiomyopathy. The company also has additional assets focused on treating fatal cardiac diseases.

The company is progressing its diverse pipeline by bringing together scientists, technologists, and experts in disease management and care. Founded by individuals directly affected by these diseases, Solid Biosciences strives to enhance the quality of life for patients suffering from these severe conditions.

Solid Biosciences places a strong emphasis on patient advocacy and aims to make a meaningful impact on the lives of those affected by rare neuromuscular and cardiac disorders.